Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation

Robert Nelson, Muhammad Rizwan Khawaja, Susan Perkins, Lindsey Elmore, Christen L. Mumaw, Christie Orschell, Sophie Paczesny

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days+7,+14,+21, and+30. At a median follow-up of 358days, 17 patients had experienced aGVHD with a median time to onset at day+36. Risk of aGVHD wasassociated with elevated plasma ST2 concentrations at day+7 (c-statistic=72, P=03), day+14 (c-statistic=74, P=02), and day+21 (c-statistic=75, P=02); elevated plasma REG3α concentrations at day+14 (c-statistic=73, P=03), day+21 (c-statistic=76, P=01), and day+30 (c-statistic=73, P=03); and elevated elafin at day+14 (c-statistic=71, P=04). Plasma concentrations of TNFR1 and sIL2Rα were not associated with aGVHD risk at any of the time points studied. Thisstudy identified ST2, REG3α, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort.

Original languageEnglish
Pages (from-to)1861-1864
Number of pages4
JournalBiology of Blood and Marrow Transplantation
Volume20
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Graft vs Host Disease
Cyclophosphamide
Biomarkers
Elafin
Tumor Necrosis Factor Receptors
Interleukin-2 Receptors
fludarabine

Keywords

  • Acute graft-versus-host-disease
  • Biomarkers
  • Nonmyeloablative allotransplantation

ASJC Scopus subject areas

  • Transplantation
  • Hematology
  • Medicine(all)

Cite this

Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation. / Nelson, Robert; Khawaja, Muhammad Rizwan; Perkins, Susan; Elmore, Lindsey; Mumaw, Christen L.; Orschell, Christie; Paczesny, Sophie.

In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 11, 01.11.2014, p. 1861-1864.

Research output: Contribution to journalArticle

@article{7d4f77a255fa4809be9332637c7f5cb6,
title = "Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation",
abstract = "Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days+7,+14,+21, and+30. At a median follow-up of 358days, 17 patients had experienced aGVHD with a median time to onset at day+36. Risk of aGVHD wasassociated with elevated plasma ST2 concentrations at day+7 (c-statistic=72, P=03), day+14 (c-statistic=74, P=02), and day+21 (c-statistic=75, P=02); elevated plasma REG3α concentrations at day+14 (c-statistic=73, P=03), day+21 (c-statistic=76, P=01), and day+30 (c-statistic=73, P=03); and elevated elafin at day+14 (c-statistic=71, P=04). Plasma concentrations of TNFR1 and sIL2Rα were not associated with aGVHD risk at any of the time points studied. Thisstudy identified ST2, REG3α, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort.",
keywords = "Acute graft-versus-host-disease, Biomarkers, Nonmyeloablative allotransplantation",
author = "Robert Nelson and Khawaja, {Muhammad Rizwan} and Susan Perkins and Lindsey Elmore and Mumaw, {Christen L.} and Christie Orschell and Sophie Paczesny",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.bbmt.2014.06.039",
language = "English",
volume = "20",
pages = "1861--1864",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation

AU - Nelson, Robert

AU - Khawaja, Muhammad Rizwan

AU - Perkins, Susan

AU - Elmore, Lindsey

AU - Mumaw, Christen L.

AU - Orschell, Christie

AU - Paczesny, Sophie

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days+7,+14,+21, and+30. At a median follow-up of 358days, 17 patients had experienced aGVHD with a median time to onset at day+36. Risk of aGVHD wasassociated with elevated plasma ST2 concentrations at day+7 (c-statistic=72, P=03), day+14 (c-statistic=74, P=02), and day+21 (c-statistic=75, P=02); elevated plasma REG3α concentrations at day+14 (c-statistic=73, P=03), day+21 (c-statistic=76, P=01), and day+30 (c-statistic=73, P=03); and elevated elafin at day+14 (c-statistic=71, P=04). Plasma concentrations of TNFR1 and sIL2Rα were not associated with aGVHD risk at any of the time points studied. Thisstudy identified ST2, REG3α, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort.

AB - Five candidate plasma biomarkers (suppression of tumorogenesis 2 [ST2], regenerating islet-derived-3α [REG3α], elafin, tumor necrosis factor receptor 1 [TNFR1], and soluble IL-2 receptor-alpha [sIL2Rα]) were measured at specific time points after cyclophosphamide/fludarabine-based nonmyeloablative allotransplantation (NMAT) in patients who did or did not develop acute graft-versus-host disease (aGVHD). Plasma samples from 34 patients were analyzed at days+7,+14,+21, and+30. At a median follow-up of 358days, 17 patients had experienced aGVHD with a median time to onset at day+36. Risk of aGVHD wasassociated with elevated plasma ST2 concentrations at day+7 (c-statistic=72, P=03), day+14 (c-statistic=74, P=02), and day+21 (c-statistic=75, P=02); elevated plasma REG3α concentrations at day+14 (c-statistic=73, P=03), day+21 (c-statistic=76, P=01), and day+30 (c-statistic=73, P=03); and elevated elafin at day+14 (c-statistic=71, P=04). Plasma concentrations of TNFR1 and sIL2Rα were not associated with aGVHD risk at any of the time points studied. Thisstudy identified ST2, REG3α, and elafin as prognostic biomarkers to evaluate risk of aGVHD after cyclophosphamide/fludarabine-based NMAT. These results need to be confirmed in an independent validation cohort.

KW - Acute graft-versus-host-disease

KW - Biomarkers

KW - Nonmyeloablative allotransplantation

UR - http://www.scopus.com/inward/record.url?scp=84908021017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908021017&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2014.06.039

DO - 10.1016/j.bbmt.2014.06.039

M3 - Article

C2 - 25017764

AN - SCOPUS:84908021017

VL - 20

SP - 1861

EP - 1864

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 11

ER -